Hypoxia

PreclinicalBiologic

UUniversity of Aarhus

Hypoxia is one of 6 biologic programs targeting Depressive Symptoms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Depressive SymptomsRecruiting

Depressive SymptomsPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Depressive Symptoms

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 2

1 2

AXS-05

AAxsome Therapeutics, Inc.

Phase 3

1 3

Psilocybin

COMPASS Pathways

Phase 1

1 4

Ci-581a

NNew York State Psychiatric Institute

Phase 2

1 5

Ci-581b

NNew York State Psychiatric Institute

Phase 2

1 6

Hypoxia

UUniversity of Aarhus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Depressive Symptoms1 trial

Going to Altitude With Anxious-depressive Symptoms

Recruiting·—·N/A·NCT05323864·68 enrolled

Hypoxia1 trial

The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo

Unknown status·UUniversity of Aarhus·Phase 2·NCT03090087·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hypoxia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hypoxia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hypoxia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Aarhus

Hypoxia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Depressive Symptoms1 trial

Hypoxia1 trial

References

Drug Info

Quick Facts

Related News